Launch Underwriters Names Former MS Transverse Executive as CEO
Launch Underwriters, an MGA platform, appoints a former MS Transverse executive as CEO, expanding its leadership with industry veterans to enhance insurance operations.
Launch Underwriters, an MGA platform, appoints a former MS Transverse executive as CEO, expanding its leadership with industry veterans to enhance insurance operations.
KATES Detective & Security Services Agency files lawsuit against insurance brokers for negligent insurance procurement, underscoring risks in corporate insurance coverage and broker responsibilities.
Explore how a $50,000 annuity can provide predictable monthly income for retirees, including payout factors like age, annuity type, and tax considerations. Understand the role of annuities in retirement income strategies amid market volatility.
Analysis of repeat DUI offenses in a fatal hit-and-run case underscores challenges for insurers in underwriting, claims, and risk management within auto insurance and regulatory compliance.
UnitedHealth Group faces a DOJ investigation for possible Medicare fraud, leading to its worst monthly stock slump and raising regulatory and market concerns in the U.S. health insurance sector.
Bene Market LLC and Seguro Medico LLC operated deceptive health and dental discount plan sales via a call center, raising compliance issues in insurance marketing.
House Energy and Commerce Committee advances Republican Medicaid overhaul expected to cut federal spending by $625 billion, introduce work requirements, and impact 10 million Americans' coverage.
Comprehensive polling reveals strong U.S. voter opposition to Medicaid cuts and work requirements, highlighting critical implications for Medicaid-funded home care and services for seniors and disabled individuals.
Explore the 2025 anniversaries of foundational U.S. laws: Social Security, Medicare, Medicaid, ADA, and ACA, highlighting their impact on insurance regulation and healthcare policy.
New analysis shows Inflation Reduction Act provisions will reduce Medicare Part D out-of-pocket costs for specialty drugs etanercept, ustekinumab, and ibrutinib, improving affordability for beneficiaries.